ArticleBiochemistry and biophysics reports2025
Investigation of Epstein-Barr virus coinfection and changes in the gene expression of angiotensin converting enzyme II in peripheral blood mononuclear cells in COVID-19 patients.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2, a respiratory virus, causes a range of symptoms from mild cold-like signs to severe conditions like pneumonia and death. Co-infections, such as with Epstein-Barr Virus (EBV), may exacerbate disease severity. EBV can remain latent in B-cells and cause symptoms including pharyngitis, fatigue, and lymphopenia upon reactivation. Studies indicate that gene expression changes in the renin-angiotensin system, particularly involving angiotensin-converting enzyme 2 (ACE2), play a role in SARS-CoV-2 infection, and EBV might increase ACE2 expression. This study investigated EBV prevalence in plasma and peripheral blood mononuclear cells (PBMCs) of COVID-19 patients using serological (ELISA) and molecular (real-time PCR) methods, while also assessing ACE2 expression levels compared to healthy controls. Blood samples were processed to isolate PBMCs and plasma. Results revealed no IgM antibodies against EBV in plasma and only 2.18 % of PBMCs were EBV-positive, indicating no active EBV infection. ACE2 expression levels in PBMCs showed no significant difference between patients and controls. The study concludes that EBV reactivation is unlikely in these COVID-19 patients and recommends further investigation of ACE2 expression in nasopharyngeal epithelial cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.